Data compiled by Redley Lamar · ChainSifter Intelligence
0Suppliers
11Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Genenta Science S.p.A. (GNTA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
15Total relationships
1Distinct source URLs
4High confidence
0.695Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Genenta Science S.p.A. Suppliers
No suppliers on recordGenenta Science S.p.A. has not yet been matched to upstream suppliers in our database, or is still being processed.
Genenta Science S.p.A. Customers
Ticker
Name
Confidence
Evidence
BLUEBIRD-BIO-INC
BLUEBIRD-BIO-INC
62%
candidate, Temferon, and any additional product candidates that we may pursue in the future; ● seek regulatory and marketing approvals for our product candidates that successfully complete clinical s…
COMIFAR-GROUP-VALTELLINA-GROUP
COMIFAR-GROUP-VALTELLINA-GROUP
62%
ions more profitably, while respecting the principle of selecting low-risk profile assets. In addition, approximately €14,000 of our cash and cash equivalents were used to primarily purchase laptops …
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
ts and the completion of clinical trial milestones. In accruing service fees, we estimate the period over which services will be performed and the level of effort to be expended in each period. If th…
GENENTA-SCIENCE-INC
GENENTA-SCIENCE-INC
62%
Note 15. Share-Based Compensation.) Currently, the Company has authorized options on 2,343,218 common shares (i.e., 10 % of the number of shares outstanding, which was 23,432,183 common shares outsta…
GEODIS-GROUP
GEODIS-GROUP
62%
ions more profitably, while respecting the principle of selecting low-risk profile assets. In addition, approximately €14,000 of our cash and cash equivalents were used to primarily purchase laptops …
GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-DEVELOPMEN
GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-DEVELOPMEN
62%
mitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In…
GMBH-CHEMO-GROUP
GMBH-CHEMO-GROUP
62%
ions more profitably, while respecting the principle of selecting low-risk profile assets. In addition, approximately €14,000 of our cash and cash equivalents were used to primarily purchase laptops …
GSK
GSK plc
62%
Reciprocal relationship from GSK graph: Reciprocal relationship from GNTA graph: mitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, revi…
LUPIN-LIMITED
LUPIN-LIMITED
62%
ions more profitably, while respecting the principle of selecting low-risk profile assets. In addition, approximately €14,000 of our cash and cash equivalents were used to primarily purchase laptops …
MAXIM-GROUP-LLC
MAXIM-GROUP-LLC
62%
sory at the end of 2025 to assist in the identification of a strategic partner to advance the development of Temferon. The Company is subject to risks and uncertainties common to clinical-stage compa…
VIRTU-AMERICAS-LLC
VIRTU-AMERICAS-LLC
62%
sory at the end of 2025 to assist in the identification of a strategic partner to advance the development of Temferon. The Company is subject to risks and uncertainties common to clinical-stage compa…
Genenta Science S.p.A. Debt Obligations
Instrument
Description
Confidence
Evidence
GNTA-DEBT-9836
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
GNTA-DEBT
Debt stack $8.8M
90%
Market cache reports total debt of $8.8M.
GNTA-DEBT-9835
Warrants outstanding: 14.375
90%
xbrl warrant detail from xbrl 2023-06-30.
Genenta Science S.p.A. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Genenta Science S.p.A..
Genenta Science S.p.A. Ownership
Holder
Name
Confidence
Evidence
GNTA-OWNER-EURIZON-CAPITAL-SGR-S-P-A
Eurizon Capital SGR S.p.A.
90%
13F overlay lists Eurizon Capital SGR S.p.A. as top holder; 11 tracked holders.
